ARTGEN THERAPEUTICS

artgen-therapeutics-logo

Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed to stimulate angiogenesis with the first indication directed for Peripheral Artery Disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen's platform technology has the potential for treatment of other vascular diseases.

#SimilarOrganizations #More

ARTGEN THERAPEUTICS

Industry:
Biotechnology

Founded:
2015-01-01

Status:
Active


Similar Organizations

anagin-logo

Anagin

Anagin is developing first-in-class therapies for treating neuropsychiatric diseases.

belx-biopharma-logo

BELX BioPharma

develop botanical new drugs for treatments of tumors, chronic liver diseases and cancers

bikam-logo

Bikam

Bikam developing novel therapies for diseases of the eye.

gene-sciences-inc-logo

Gene Sciences, Inc.

Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.

uniquity-bio-logo

Uniquity Bio

Uniquity Bio operates as a drug development company.

tavec-pharma-logo

Tavec pharma

Tavec Pharmaceuticals is developing injectable therapies to treat cancers.

More informations about "Artgen Therapeutics"

ArtGene Therapeutics - Artgen biotech

ArtGene Therapeutics is a partner company that holds an intellectual property license for the Neovasculgen drug and developments created outside the Russian Federation and the CIS. …See details»

Artgen biotech - Group Structure

Organization of wholesale sales and drugs for the Artgen group company. ... ArtGene Therapeutics ... info@artgen.ru +7 (495) 646-80-76 ©2003-2024 Artgen biotech About the …See details»

Artgen Therapeutics - Crunchbase Company Profile

Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed …See details»

Artgen biotech - About the Company

Artgen is a biotechnology company with a portfolio of developments whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, …See details»

Artgen Therapeutics - Crunchbase

Artgen Therapeutics, Gene Sciences Inc., Anagin, Tavec Pharmaceuticals, Bikam, and BELX BioPharma are all involved in the biopharmaceutical industry. Artgen and Gene Sciences …See details»

ArtGene Therapeutics - Артген биотех

ArtGene Therapeutics 是拥有与涅奥瓦斯库尔根药物相关并在俄罗斯联邦和独立国家联合体之外开发的知识产权许可的一家合作公司。该公司进行临床前和临床检验,开发ART-101药物,这是 …See details»

PJSC "ARTGEN": owners, founders, management, details (TIN …

Nov 22, 2024 Full name of the organization: PUBLIC JOINT-STOCK COMPANY «ARTGEN BIOTECH» TIN: 7702508905 KPP: 773601001 PSRN: 1037789001315 Location: 119333, …See details»

Artgen biotech Company Profile 2024: Stock Performance

Artgen biotech General Information Description. Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and …See details»

Artgen Biotech is a biotechnology company

Artgen is a biotechnology company bringing to healthcare a portfolio of innovative platform developments. About It includes companies of different development stages: from seed to early growth and maturity, as well as those forming the …See details»

Artgen Biotech - Company Profile - Tracxn

Artgen Biotech has 359 competitors. Artgen Biotech - Company developing biomedical products, including vaccines, antibodies, and gene therapy drugs. Artgen Biotech - Company Profile - …See details»

ArtGen - Products, Competitors, Financials, Employees, …

About ArtGen. Developer of a gene therapy drug. The company has been licensed the exclusive U.S. and Canadian rights for Neovasculgen, first-in-class gene therapy drug that was …See details»

Artgen Biotech PJSC Company Description - Stock Analysis

Jul 8, 2022 Artgen Biotech PJSC, a biotech company, engages in the development of healthcare products in Russia. It develops Betuvax-CoV-2, a vaccine for SARS-COV-2; Tetraflubet, a Flu …See details»

Artgen Company Profile 2024: Valuation, Funding & Investors

Artgen General Information Description. Provider of biotechnology services based in Rockville, Maryland. The company specializes in providing biotechnology services including …See details»

US billionaire Gerald Chan returns to back UCC spin-out Artugen

Feb 18, 2022 University College Cork (UCC) spin-out Artugen Therapeutics has secured a further $5 million (€4.4 million) in funding from Morningside Group, an investment firm founded …See details»

Nextgen

The action of the drug is fundamentally different from all known drugs for the treatment of chronic lower limb ischemia (CLI). This is the world’s first gene therapy drug based on the “therapeutic …See details»

Artugen Therapeutics Company Profile 2024: Valuation, Investors ...

Artugen Therapeutics’s most recent deal was a Merger of Equals with Adiso Therapeutics. The deal was made on 10-Mar-2022. The deal was made on 10-Mar-2022. Company NameSee details»

Artugen Therapeutics - Crunchbase Company Profile & Funding

Artugen Therapeutics offers biotherapeutics products to help people with difficult-to-treat infectious and inflammatory diseases that are modulated by the GI tract. They apply sound …See details»

Artgen biotech - Drugs – Artgen biotech

Developer: ArtGene Therapeutics , Nextgen . Genotarget. Development of gene therapy drugs for the treatment of rare neuromuscular diseases. Drug. Indication. DSCVRY. Preclinical ...See details»

Vistagen Therapeutics, Inc - Developing Innovative Medications …

Vistagen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem …See details»

Artgen biotech - Development Portfolio

Info@artgen.ru +7 (495) 646-80-76 ©2003-2024 Artgen biotech About the Company; Company Strategy; Group Structure; Board of Directors; Management; Career; Contacts; Development …See details»

linkstock.net © 2022. All rights reserved